Trade CTMX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
CytomX Therapeutics, Inc. (CTMX) is trading at US$3.42, up 3.01% today as of Aug 27, 16:00 EDT. The company has a market capitalisation of US$714.71M. Over the past 52 weeks, CTMX has traded between US$1.90 and US$8.21. On Syfe you can trade CTMX with $0 commission and add it to your watchlist.
| Previous close | US$3.32 |
|---|---|
| Market cap | US$714.71M |
| 52-week range | US$1.90 – US$8.21 |
| Volume | 2.58M |
| Exchange | US |
Add to Watchlist
Set Price Alert
CytomX Therapeutics, Inc.
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Year: 2015
CytomX Therapeutics Expands Cancer Therapy Partnership With Regeneron; Shares Rise
Jun 3, 1:21 PM · MT Newswires
Wolfe Research Initiates CytomX Therapeutics With Outperform Rating
May 19, 12:12 PM · MT Newswires
-- Earnings Flash (CTMX) CytomX Therapeutics, Inc. Reports Q1 Revenue $10.3M, vs. FactSet Est of $4.7M
May 7, 8:28 PM · MT Newswires
Cytomx Therapeutics Insider Sold Shares Worth $764,138, According to a Recent SEC Filing
Mar 20, 8:25 AM · MT Newswires
CytomX Therapeutics, Inc. (CTMX) stock is trading at US$3.42, +3.01% from the previous close of US$3.32.
The market cap for CytomX Therapeutics, Inc. (CTMX) stock is approximately US$714.71M.
The 52-week high for CytomX Therapeutics, Inc. (CTMX) stock is US$8.21.
The 52-week low for CytomX Therapeutics, Inc. (CTMX) stock is US$1.90.
CytomX Therapeutics, Inc. (CTMX) does not currently pay a dividend.
Stay on top of CTMX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
